Zenas BioPharma, Inc. (ZBIO) Stock Analysis

Q: What is the ZBIO stock price target?

Take-profit $36.65 (+116.7% upside). Prior stop was $15.92.

Q: Is ZBIO overvalued or undervalued?

Zenas BioPharma, Inc. trades at a P/E of N/A (forward -96.5). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about ZBIO?

14 analysts cover ZBIO with a consensus score of 4.4/5. Average price target: $42.

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2 days ago (May 18, 2026, 8:51 PM ET)

Healthcare · Biotechnology

$17.04+116.7% A.UpsideScore 5.1/10#93 of 157 Biotechnology

QualityF-score4 / 9FCF yield-14.36%

Stop $15.92Target $36.65(analyst − 13%)A.R:R 7.8:1

Analyst target$42.13+147.2%8 analysts

$36.65our TP

$17.04price

$42.13mean

$55

Sell if holding. Engine safety override at $17.04: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, no SEC red flags, news boost analyst 0.80, earnings proximity 86d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: aggressive.

Recent Developments — Zenas BioPharma, Inc.

Latest news

Zenas BioPharma Announces That Safety And Efficacy Outcomes From The Phase 3 INDIGO Trial Will Be Presented At The Europ — benzinga May 19, 2026 positive
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target — benzinga May 15, 2026 positive
Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $22 — benzinga May 14, 2026 neutral
Earnings Scheduled For May 13, 2026 — benzinga May 13, 2026 neutral
Zenas BioPharma Does First Patient In Its Phase 1 Trial Of ZB021, A Novel Oral IL-17AA/AF Inhibitor — benzinga May 13, 2026 positive

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

Recent Analyst detected in news

Risks

Quality below floor (1.5 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-96.5

Mkt Cap$1.2B

EV/EBITDA-2.8

Profit Mgn0.0%

ROE-137.1%

Rev Growth—

Beta—

DividendNone

Rating analysts14

Quality Signals

Piotroski F4/9

Options Flow

P/C1.00neutral

IV101%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.515%0.22

Growth5.015%0.75

Momentum3.610%0.36

Sentiment7.710%0.77

Insider Activity7.410%0.74

Peer Rank2.510%0.25

Technical Setup6.45%0.32

Risk Profile2.35%0.11

Catalyst3.65%0.18

Overall (Σ contributions)5.06

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Moat

4.0

Piotroski F

4.4

Current Ratio

5.0

Cash-burning (FCF negative)No competitive moatQuality concerns

Volatile — 9.2% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Implied Vol

0.0

Short Interest

0.9

Debt Equity

6.2

Put Call

6.7

High short interest justified: 26%High IV: 101%

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.0

Value Rank

5.0

Growth Rank

5.0

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv

1.0

Macd

1.3

Ma Position

2.2

Vol Acceleration

2.9

Rsi

4.5

Volume

10.0

Volume distribution (falling OBV)Below 200-MA but MA still rising (+5.0%/30d) — pullback in uptrend, not confirmed weaknessVolume surge (2.1x avg) on selloff

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

News Activity

8.0

Earnings concerns: 1B/3M

GatesMomentum 3.6<4.5INSIDER 0.57%=EXTREMEA.R:R 7.8 ≥ 1.5No SEC red flagsNEWS BOOST ANALYST 0.80EARNINGS PROXIMITY 86d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

46 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $16.41Resistance $22.15

Price Targets

$16

$37

A.Upside+115.1%

A.R:R7.8:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.5 < 4.0)

! Momentum score 3.6/10 — below 4.5 minimum

! Insider activity: 0.57%=extreme

Earnings

1/4 beats

Next Earnings2026-08-12 (86d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is ZBIO stock a buy right now?

Sell if holding. Engine safety override at $17.04: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $15.92. Score 5.1/10, moderate confidence.

What is the ZBIO stock price target?

Take-profit target: $36.65 (+116.7% upside). Prior stop was $15.92. Stop-loss: $15.92.

What are the risks of investing in ZBIO?

Quality below floor (1.5 < 4.0).

Is ZBIO overvalued or undervalued?

Zenas BioPharma, Inc. trades at a P/E of N/A (forward -96.5). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about ZBIO?

14 analysts cover ZBIO with a consensus score of 4.4/5. Average price target: $42.

What does Zenas BioPharma, Inc. do?Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of...

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.